Abstract | PURPOSE: EXPERIMENTAL DESIGN: Patients were treated with docetaxel at doses ranging from 60 to 75 mg/m(2) every 21 days, with daily oral atrasentan 10 mg starting on day 3. Patients were treated until evidence of disease progression or unacceptable toxicity. RESULTS: Thirty-one patients were enrolled over three docetaxel dose levels (8 at 60 mg/m(2), 19 at 70 mg/m(2), and 4 at 75 mg/m(2)) including dose expansion at 70 mg/m(2). The maximum tolerated dose of docetaxel was 70 to 75 mg/m(2). Drug-related grade 3-4 toxicities included neutropenia (50-63%) and febrile neutropenia (16-25%); other grade 1-2 toxicities included fatigue, peripheral edema, diarrhea, headache, rhinitis, anorexia, and nausea. Confirmed prostate-specific antigen (PSA) responses were observed in 23% [95% confidence interval (95% CI), 10-41%]; the rate of >30% declines in PSA was 35% (95% CI, 19-55%). Median overall survival was 17.6 months (95% CI, 13.0-23.2) and median progression-free survival was 4.2 months (95% CI, 2.3-5.8). Significant declines in bone alkaline phosphatase and serum N-telopeptides were observed with therapy. CONCLUSIONS: The maximum tolerated dose of every-3-week docetaxel with 10 mg atrasentan is 70 to 75 mg/m(2). Overall survival and progression-free survival are comparable to that seen with docetaxel and prednisone, whereas the rates of PSA decline are slightly lower than expected. A phase III study of this combination with prednisone has been initiated and is ongoing.
|
Authors | Andrew J Armstrong, Patricia Creel, James Turnbull, Cassandra Moore, Tracy A Jaffe, Sherri Haley, William Petros, Sarah Yenser, Jon P Gockerman, Darryl Sleep, Herbert Hurwitz, Daniel J George |
Journal | Clinical cancer research : an official journal of the American Association for Cancer Research
(Clin Cancer Res)
Vol. 14
Issue 19
Pg. 6270-6
(Oct 01 2008)
ISSN: 1078-0432 [Print] United States |
PMID | 18829508
(Publication Type: Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Pyrrolidines
- Taxoids
- Docetaxel
- Atrasentan
|
Topics |
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Atrasentan
- Disease Progression
- Disease-Free Survival
- Docetaxel
- Drug Resistance, Neoplasm
- Humans
- Male
- Maximum Tolerated Dose
- Middle Aged
- Neoplasm Metastasis
- Prostatic Neoplasms
(drug therapy, pathology)
- Pyrrolidines
(administration & dosage)
- Taxoids
(administration & dosage)
- Treatment Outcome
|